(APM) – Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer


Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer

The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma.

  • Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in 2022.
  • Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% – 10% of all childhood tumors, accounting for around 15% of all cancer-related deaths in the pediatric population.
  • Aptorum received its first US patent regarding SACT-1 repurposed drug for various cancers earlier this week.
  • The SACT-1 invention provides a composition and method for treating or preventing the growth of cancerous tumors and/or delaying the onset of cancer from tumor-initiating cells. 
  • Price Action: APM shares are up 30.3% at $1.59 during the premarket session on the last check Thursday.



Source link


Leave a Reply